Exagen awards director 37,500 stock options

Rhea-AI Filing Summary

EXAGEN INC. (XGN) reported that director Paul Kim received a grant of stock options. On 2026-06-09, he was awarded 37,500 stock options to purchase common stock at an exercise price of $4.31 per share, expiring on 2036-06-08. These options vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, subject to his continued board service. Following this grant, Kim holds 46,500 options directly.

Insider Trade Summary

Grant/Award: 37,500 shares

Grant/Award 1 txn

Insider Kim Paul

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option(right to buy) F1	37,500	$0.00	$0.00

Holdings After Transaction: Stock Option(right to buy) — 46,500 contracts (Direct)

Footnotes (1)

1. F1. The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Key Figures

Options granted: 37,500 options Exercise price: $4.31 per share Expiration date: 2036-06-08 +3 more

6 metrics

Options granted 37,500 options Stock option grant to Paul Kim on 2026-06-09

Exercise price $4.31 per share Conversion or exercise price of granted stock options

Expiration date 2036-06-08 Expiration of the granted stock options

Underlying shares 37,500 shares Common shares underlying the granted options

Total options after grant 46,500 options Paul Kim’s derivative holdings following the reported transaction

Affirmed 10b5-1 plan status false Form-level checkbox for Rule 10b5-1(c) plan

Key Terms

Stock Option(right to buy), exercise price, vesting, annual meeting of the Issuer's stockholders

4 terms

Stock Option(right to buy) financial

"security_title: Stock Option(right to buy)"

exercise price financial

"conversion_or_exercise_price: 4.3100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"becomes fully vested and exercisable on the first to occur"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of the Issuer's stockholders financial

"or (b) the next occurring annual meeting of the Issuer's stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Paul Kim report on Form 4 for EXAGEN INC. (XGN)?

Paul Kim reported a grant of stock options from Exagen Inc. He received 37,500 options on 2026-06-09 to buy common stock, representing compensation rather than an open-market purchase or sale.

How many EXAGEN INC. (XGN) stock options were granted to Paul Kim and at what price?

Paul Kim was granted 37,500 stock options with an exercise price of $4.31 per share. These options give him the right to purchase Exagen common stock at that price until expiration if they vest and are exercised.

When do Paul Kim’s EXAGEN INC. (XGN) stock options vest?

All 37,500 options vest in full on the earlier of the first anniversary of the 2026-06-09 grant date or the next annual meeting of stockholders, provided Kim continues serving on Exagen’s board through the vesting date.

What is the expiration date of Paul Kim’s EXAGEN INC. (XGN) stock options?

The granted options expire on 2036-06-08. After that expiration date, any unexercised options will no longer be exercisable, so value can only be realized if exercised before this deadline subject to vesting conditions.

How many EXAGEN INC. (XGN) stock options does Paul Kim hold after this grant?

After the 37,500-option grant, Paul Kim directly holds 46,500 stock options in total. This figure reflects his derivative holdings reported following the transaction on the Form 4 filing for Exagen Inc.

Was Paul Kim’s EXAGEN INC. (XGN) Form 4 transaction under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as relying on a 10b5-1 plan. The reported transaction is a compensation-related option grant rather than a pre-arranged open-market trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/19/2026 - 06:57 PM Accepted by SEC EDGAR 08/19/2026 - 06:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kim Paul

(Last) (First) (Middle)

C/O EXAGEN INC.

1261 LIBERTY WAY

(Street)

VISTA CALIFORNIA 92081

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
EXAGEN INC. [ XGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option(right to buy)	$4.31	06/09/2026		A		37,500		06/09/2026(1)	06/08/2036	Common Stock	37,500	$0	46,500	D

Explanation of Responses:

1. The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Remarks:

	/s/ Jeffrey G. Black, as attorney-in-fact	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)